Report : North America Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others)
At 9.9% CAGR, North America Microbiome Therapeutics Market is Speculated to be Worth US$ 342.99 Million by 2030, Says Business Market Insights
According to Business Market Insights' research, the North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030, registering a CAGR of 9.9% from 2022 to 2030. Potential of gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline are among the critical factors attributed to the North America microbiome therapeutics market expansion.
Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.
On the contrary, high cost of development and production hampers the growth of North America microbiome therapeutics market.
Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held 98.2% share of the North America microbiome therapeutics market in 2022, amassing US$ 158.78 million. It is projected to garner US$ 332.31 million by 2030 to expand at 9.7% CAGR during 2022-2030. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.
By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held 92.2% share of the North America microbiome therapeutics market in 2022, amassing US$ 148.96 million. It is projected to garner US$ 317.99 million by 2030 to expand at 9.9% CAGR during 2022-2030.
By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held 55.4% share of the North America microbiome therapeutics market in 2022, amassing US 89.53 million. It is projected to garner US$ 195.94 million by 2030 to expand at 10.3% CAGR during 2022-2030.
Based on country, the North America microbiome therapeutics market is segmented into US, Canada, and Mexico. The US held 83.2% share of North America microbiome therapeutics market in 2022, amassing US$ 134.50 million. It is projected to garner US$ 288.23 million by 2030 to expand at 10.0% CAGR during 2022-2030.
Key players operating in the North America microbiome therapeutics market are AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com